Recurrence Patterns of Stage III Melanoma and Implications on Follow-Up Guidelines

Congress:

2016 ASM

Poster Number:

R-0025

Type:

Educational Exhibit

Keywords:

Oncology, Soft tissues / Skin, CT, Diagnostic procedure, Cancer

Authors:

T. Tan, D. Loh, T. Lo, M. Bressel, M. Chua, V. Estall, M. Johnston, K. Pope; VIC/AU

DOI:

10.1594/ranzcr2016/R-0025

DOI-Link:

https://dx.doi.org/10.1594/ranzcr2016/R-0025

References

Australian Institute of Health and Welfare. Cancer in Australia: An overview, 2014. AIHW cat.no. CAN 88. Canberra, Australia; 2014 Available from: www.aihw.gov.au.
Balch C. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-34.
Joseph R. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32(5s).
Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma. J Clin Oncol. 2014;32(5s).
Romano E, Scordo M, Dusza S, Coit D, Chapman P. Site and Timing of First Relapse in stage III Melanoma Patients: Implications for Follow-Up Guidelines. Journal of Clinical Oncology. 2010;28(18):3042-3047.